Concord Biotech Limited approved audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The board of directors approved the results at a meeting held on May 29, 2026. The meeting commenced at 3:00 PM and concluded at 4:24 PM. The board considered and approved the results along with other agenda items.
The board recommended a dividend of Rs 7.55 per equity share of face value Re 1 each for the financial year 2025-26. The record date for determining shareholders eligible for the dividend has been fixed as July 24, 2026. The dividend payout is subject to approval by shareholders at the annual general meeting.
The board appointed Mrs. Ekta Gupta as an Additional Independent Director with effect from June 1, 2026, for a term of five consecutive years, subject to shareholder approval. The appointment was made on the recommendation of the Nomination and Remuneration Committee. She holds an MBA in Finance from Cardiff University and serves as Director of Sanghi Polymers Private Limited.
The board also approved the standalone and consolidated audited financial statements for the financial year ended March 31, 2026. The directors' report was approved at the same meeting. Concord Biotech confirmed no deviation in the use of proceeds from its public issue and reported no outstanding defaults on loans or debt securities.
Concord Biotech Limited is listed on the BSE and NSE under the symbol CONCORDBIO. The disclosures were submitted to the stock exchanges following the board meeting.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.